Business
Alkermes to Participate in the Stifel 2023 CNS Days
DUBLIN, March 15, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the Stifel
About this update from Alkermes Plc
[{"type":"text","content":"DUBLIN, March 15, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the Stifel 2023 CNS Days on Wednesday, March 29, 2023 at 9:00 a.m. ET (2:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.\nAbout Alkermes plc\nAlkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.\nAlkermes Contact: Jamie BernardInvestor Relations+1 781 873 2402\n\n \n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-stifel-2023-cns-days-301773137.html\nSOURCE Alkermes plc","length":2894,"tagName":"div"}]